Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Authors
Keywords
-
Journal
Cell Communication and Signaling
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-07
DOI
10.1186/s12964-022-00838-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
- (2021) Kai-Lin Yang et al. Radiation Oncology
- Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma
- (2021) Hikaru Kubota et al. Radiation Oncology
- Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer
- (2021) Pingping Liang et al. ADVANCED MATERIALS
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
- (2021) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
- (2021) Anna Wrona et al. Translational Lung Cancer Research
- Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment
- (2021) Linbang Wang et al. Experimental Hematology & Oncology
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
- (2021) Chung-Han Lee et al. LANCET ONCOLOGY
- HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis
- (2020) Yanling Niu et al. CANCER RESEARCH
- Ramucirumab: A Review in Hepatocellular Carcinoma
- (2020) Yahiya Y. Syed DRUGS
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
- (2020) Qiaohong Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II study of 5-fluorouracil–leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)
- (2020) Takashi Ohta et al. International Journal of Clinical Oncology
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma
- (2020) Pedro Miguel Lacal et al. PHARMACOLOGICAL RESEARCH
- Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
- (2020) Ian Chau et al. Cancers
- Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
- (2020) Vivek Subbiah et al. Experimental Hematology & Oncology
- Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
- (2020) Yung-Jue Bang et al. EUROPEAN JOURNAL OF CANCER
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
- (2020) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer
- (2020) Benoist Chibaudel et al. JAMA Network Open
- Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
- (2020) Ramón Salazar et al. BMC CANCER
- Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
- (2020) Elisabeth Pérez-Ruiz et al. DRUG RESISTANCE UPDATES
- Heparanase and the hallmarks of cancer
- (2020) Krishnath M. Jayatilleke et al. Journal of Translational Medicine
- Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
- (2019) Nieves Martínez Chanzá et al. LANCET ONCOLOGY
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- VEGF/Neuropilin Signaling in Cancer Stem Cells
- (2019) Arthur Mercurio INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogate glioma invasion via the CCN1 and AKT signaling pathways
- (2019) Yusuke Tomita et al. MOLECULAR CANCER THERAPEUTICS
- Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
- (2019) Emma Boydell et al. Cancers
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
- (2019) Breelyn A Wilky et al. LANCET ONCOLOGY
- IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis
- (2019) Erin Fahey et al. Frontiers in Immunology
- Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer
- (2019) Stephanie O. Dudzinski et al. Journal for ImmunoTherapy of Cancer
- Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
- (2019) Caterina Lapenta et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
- (2019) Martin Reck et al. Expert Review of Respiratory Medicine
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- Contribution of Angiogenesis to Inflammation and Cancer
- (2019) Dolores Aguilar-Cazares et al. Frontiers in Oncology
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
- (2018) Dipongkor Saha et al. CLINICAL CANCER RESEARCH
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
- (2018) Ahmed M.E. Abdalla et al. Theranostics
- Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
- (2018) Jia Ruan et al. BLOOD
- Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
- (2018) Chun-Yan Lan et al. LANCET ONCOLOGY
- Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma
- (2018) Ajay K. Nooka et al. JAMA Oncology
- Pro-angiogenic peptides in biomedicine
- (2018) Lucia De Rosa et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
- (2018) Florence T. H. Wu et al. BRITISH JOURNAL OF CANCER
- Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
- (2018) Qing Zhang et al. Journal of Immunology Research
- The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
- (2018) Chloé Grasselly et al. Frontiers in Immunology
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells
- (2017) Florent Colomb et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
- (2017) Jian Hou et al. Journal of Hematology & Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
- (2017) Heather A Wakelee et al. LANCET ONCOLOGY
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer
- (2017) Benjamin S. Jones et al. LUNG CANCER
- A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer
- (2017) Zhifei Zhao et al. MEDICINE
- Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
- (2017) Divya Sakamuri et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
- (2017) Simron Singh et al. NEUROENDOCRINOLOGY
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
- (2017) Manh-Cuong Vo et al. Oncotarget
- Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
- (2017) Margaret E. Gatti-Mays et al. Human Vaccines & Immunotherapeutics
- Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
- (2017) Xinqi Wu et al. Cancer Immunology Research
- Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
- (2017) Alessandro Leonetti et al. Therapeutics and Clinical Risk Management
- Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
- (2017) Paola Bocca et al. OncoImmunology
- Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review
- (2017) Ahmed M. Al-Abd et al. Journal of Advanced Research
- Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On
- (2017) James J. Lee et al. Journal of Oncology Practice
- 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
- (2017) A. Amin et al. ANNALS OF ONCOLOGY
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
- (2017) Michiru Nishita et al. Scientific Reports
- Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas
- (2016) Saori Okamoto et al. Brain Tumor Pathology
- Lenvatinib: Role in thyroid cancer and other solid tumors
- (2016) Maria E. Cabanillas et al. CANCER TREATMENT REVIEWS
- Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
- (2016) K. A. Lawson et al. CLINICAL CANCER RESEARCH
- Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study
- (2016) Alessio Giuseppe Morganti et al. Future Oncology
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma
- (2016) Qi Huang et al. Scientific Reports
- Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
- (2016) Helena Verdaguer et al. Therapeutic Advances in Medical Oncology
- Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
- (2016) Awalpreet S. Chadha et al. PLoS One
- Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
- (2015) Igor M Bondarenko et al. BMC CANCER
- Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
- (2015) V Pernin et al. BRITISH JOURNAL OF RADIOLOGY
- Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
- (2015) Thanh-Nhan Nguyen-Pham et al. JOURNAL OF IMMUNOTHERAPY
- Endostatin Combined with Platinum-Based Chemo-radiotherapy for Advanced Non-small Cell Lung Cancer
- (2014) Xuan Jiang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft
- (2014) Gewen Tan et al. INTERNATIONAL JOURNAL OF CANCER
- FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I–II study
- (2014) Alessio G. Morganti et al. JOURNAL OF CHEMOTHERAPY
- Third-line dovitinib in metastatic renal cell carcinoma
- (2014) Manuela Schmidinger LANCET ONCOLOGY
- Epidermal Growth Factor-like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer
- (2014) T. F. Hansen et al. MOLECULAR CANCER THERAPEUTICS
- Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer
- (2014) Jing-Ping Yu WORLD JOURNAL OF GASTROENTEROLOGY
- The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
- (2014) Dongjun Luo et al. Biomed Research International
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
- (2014) Theerawut Chanmee et al. Cancers
- Control of the Immune Response by Pro-Angiogenic Factors
- (2014) Thibault Voron et al. Frontiers in Oncology
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
- (2013) H Chen et al. BRITISH JOURNAL OF CANCER
- Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer
- (2013) X. Jiang et al. Clinical & Translational Oncology
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
- (2013) Prakash Vempati et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Angiopoietin signaling in the vasculature
- (2013) Lauri Eklund et al. EXPERIMENTAL CELL RESEARCH
- Endoplasmic Reticulum (ER) Stress and Hypoxia Response Pathways Interact to Potentiate Hypoxia-inducible Factor 1 (HIF-1) Transcriptional Activity on Targets Like Vascular Endothelial Growth Factor (VEGF)
- (2013) Ethel R. Pereira et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma
- (2013) Hansen Bow et al. JOURNAL OF NEUROSURGERY
- Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas
- (2013) I Sakamaki et al. LEUKEMIA
- A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma
- (2013) R. Gyanchandani et al. MOLECULAR CANCER RESEARCH
- Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
- (2013) Babal K Jha et al. MOLECULAR THERAPY
- Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis
- (2013) Xing-Lin Chen et al. PLoS One
- Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
- (2013) Shujing Shi et al. PLoS One
- The Critical Impact of HIF-1a on Gastric Cancer Biology
- (2013) Yoshihiko Kitajima et al. Cancers
- Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms
- (2012) Stacey D. Finley et al. AAPS Journal
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents
- (2012) Bulent Cetin et al. Asian Pacific Journal of Cancer Prevention
- Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination and survival of ovarian carcinoma xenograft models
- (2012) P Oliva et al. BRITISH JOURNAL OF CANCER
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Angiopoietins in angiogenesis
- (2012) Ernesta Fagiani et al. CANCER LETTERS
- A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
- (2012) Edward B. Garon et al. Clinical Lung Cancer
- VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
- (2012) P. S. Sharma et al. CURRENT CANCER DRUG TARGETS
- HIFs, angiogenesis, and cancer
- (2012) Yongzhi Yang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
- (2012) Federica Maione et al. JOURNAL OF CLINICAL INVESTIGATION
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model
- (2012) Anamika Bose et al. MELANOMA RESEARCH
- Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
- (2012) Zhong-Zhen Guan et al. Chinese Journal of Cancer
- Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects
- (2011) Zhiyun He et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Abstract 1401: Evaluation of vandetanib (ZD6474) and radiation therapy in an orthotopic xenograft model of anaplastic thyroid carcinoma
- (2011) Yunyun Chen et al. CANCER RESEARCH
- Vandetanib
- (2011) Helen Commander et al. DRUGS
- The role of pericytes in angiogenesis
- (2011) Domenico Ribatti et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
- (2011) Bryan J. Schneider et al. Journal of Thoracic Oncology
- Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer
- (2011) Isamu Okamoto et al. Journal of Thoracic Oncology
- Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
- (2011) R Grepin et al. ONCOGENE
- Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
- (2011) Vaneja Velenik et al. Radiation Oncology
- Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial
- (2011) Gudrun Resch et al. RADIOTHERAPY AND ONCOLOGY
- Angiogenesis
- (2011) D. R. Senger et al. Cold Spring Harbor Perspectives in Biology
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Angiogenesis Inhibitors: Current Strategies and Future Prospects
- (2010) K. M. Cook et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
- (2010) Camillo Porta et al. KIDNEY INTERNATIONAL
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- Bevacizumab (Avastin)
- (2009) S.K. Mukherji AMERICAN JOURNAL OF NEURORADIOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab
- (2009) M. I. Koukourakis et al. CLINICAL CANCER RESEARCH
- Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity
- (2009) Jia Hu et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis
- (2009) Y. Carmi et al. JOURNAL OF IMMUNOLOGY
- Systemic effects of local radiotherapy
- (2009) Silvia C Formenti et al. LANCET ONCOLOGY
- Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
- (2009) A. Rapisarda et al. MOLECULAR CANCER THERAPEUTICS
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Bevacizumab
- (2008) Paul L McCormack et al. DRUGS
- Cytokine regulation networks in the cancer microenvironment
- (2008) Bor-Ching Sheu Frontiers in Bioscience-Landmark
- Lenalidomide in the treatment of multiple myeloma: a review
- (2008) X. Armoiry et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
- (2008) J. Ma et al. MOLECULAR CANCER THERAPEUTICS
- Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
- (2008) J. Ma et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation